Abstract
Summary
Most patients with testis cancer are cured with treatment. However, the incidence of osteoporosis after prolonged follow-up is unknown. This study investigates the incidence of osteoporosis in 39 testis cancer patients with follow-up from 5 to 28 years. There was no increased incidence of osteoporosis. These initial data are reassuring but require further investigation.
Introduction
The majority of patients with testis cancer are cured with either a unilateral orchidectomy alone or orchidectomy and chemotherapy. However, the long-term incidence of osteoporosis following treatment for testicular cancer has not been established.
Method
This was a single-centre cross-sectional study, where bone mineral density (BMD) measurements were performed in male patients who were previously treated for testicular cancer. BMD measurements were made by dual-energy X-ray scanning (DXA) using a HOLOGIC imaging bone densitometer. The World Health Organisation criteria were used to define osteoporosis and osteopenia. Blood samples were taken from each patient at the time of the DXA scan. Statistical analyses were performed in STATA10.
Results
Neither orchidectomy alone nor orchidectomy and chemotherapy together predisposed to osteoporosis [p value = 0.4 (95%CI −0.1–0.8) and p value = 0.2 (95%CI −0.2–0.7), respectively]. Analysis also showed no evidence of an association between cases of osteopenia and length of follow-up (assessed by logistic regression).
Conclusion
This work found no association between treatment for testis cancer and the development of osteoporosis. Screening the whole population of testis cancer survivors for osteoporosis in the long term is not necessary; however, targeting specific patients with risk factors may be warranted.
References
Barrett-Connor E (1995) The economic and human costs of osteoporotic fracture. Am J Med 98:3S–8S
Riggs BL, Melton LJ 3rd (1992) The prevention and treatment of osteoporosis. N Engl J Med 327:620–627
Loehrer PJ, Einhorn LH (1984) Drugs five years later. Cisplatin. Ann Intern Med 100:704–713
Parvinen LM, Kilkku P, Makinen E et al (1983) Factors affecting the pulmonary toxicity of bleomycin. Acta Radiol Oncol 22:417–421
van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW et al (1994) Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12:1063–1073
Legrand E, Hedde C, Gallois Y et al (2001) Osteoporosis in men: a potential role for the sex hormone binding globulin. Bone 29:90–95
Raghavan D, Davis MS, Tsao-Wei D et al (2006) Increased late toxicity in 12–20 year survivors of germ cell tumors (GCT). J Clin Oncol (Meeting Abstracts) 24:4509
Brown JE, Ellis SP, Silcocks P et al (2006) Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma. Clin Cancer Res 12:6480–6486
Pfeilschifter J, Diel IJ (2000) Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18:1570–1593
Acknowledgements
This work was made possible due to a grant from the Orchid Cancer Appeal.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Murugaesu, N., Powles, T., Bestwick, J. et al. Long-term follow-up of testicular cancer patients shows no predisposition to osteoporosis. Osteoporos Int 20, 1627–1630 (2009). https://doi.org/10.1007/s00198-008-0793-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-008-0793-x